The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers

Autor: Cremers, R, Eeles, RA, Bancroft, EK, Ringelberg, J, Vasen, HF, van Asperen, CJ, Schalken, JA, Verhaegh, GW, Kiemeney, LA, Aaronson, N, Ardem-Jones, A, Bangma, C.H., Castro, E, Dearnaley, D, Eccles, D, Evans, DGR, Eyfjord, J, Falconer, A, Foster, CS (Christopher), Gronberg, H, Hamdy, FC, Johansson, O, Khoo, V, Kote-Jarai, Z, Lija, H, Lubinski, J, Maehle, L, Melia, J, Mikropoulos, C, Mitchell, G, Mitra, AV, Moss, S, Moynihan, C, Page, EC, Rennert, G, Suri, M, Wilson, P

Publikováno v: Urologic Oncology-Seminars and Original Investigations, 33(5), 202e19-202e28. Elsevier Inc.
Urologic Oncology-Seminars and Original Investigations, 33, 202.e19-28
Urologic Oncology-Seminars and Original Investigations, 33, 5, pp. 202.e19-28

Contains fulltext : 154257.pdf (Publisher’s version ) (Open Access) OBJECTIVE: To evaluate the additive value of the prostate cancer gene 3 (PCA3) urine test to serum prostate-specific antigen (PSA) in prostate cancer (PC) screening among breast ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::726fb51518c1323457bfa8d263a39693